How much they sold
About 352.5m
Operating income / revenue in 2025.
Simple version
Explain it like I’m ten
Numbers from the 2025 accounts. [R2025]
Did they make money?
-69.6m
Net result for 2025.
What’s left in the company
Equity 18.5m
Book equity at year-end.
Cash
11.7m
Bank deposits and cash (when disclosed).
At a glance · 2025
Key figures
Revenue / sales
352 523 392
NOK · [R2025]
Net result
-69 620 391
NOK · [R2025]
Equity
18 463 486
NOK · [R2025]
Cash
11 665 259
NOK · [R2025]
Total assets
185 094 511
NOK · [R2025]
Paid-in equity
88 083 877
NOK · [R2025]
Trends
5-year arc
Charts use figures extracted from published annual reports.
Sales / revenue
Equity & cash
Cost / investment lines
Salary costs (lønnskostnader)
FTEs (årsverk)
From notes when disclosed; blank years mean not found in OCR.
Analyst briefing
Company read — signals, board & numbers
Auto-written from filings, Brreg kunngjøringer, board timeline, address history, and the signal board. Interpretive — not investment advice.
Year by year
Comparing consecutive annual reports
Each filing pair has a dedicated, crawlable article page. Below is a preview of the latest comparison.
Executive summary
Auto-generated from filings
AGILERA PHARMA AS · 5 published annual accounts (2021–2025). Latest year revenue 352.5m NOK, net result -69.6m NOK, equity 18.5m NOK, cash 11.7m NOK. Figures from Brønnøysund årsregnskapskopi / nøkkeltall. Interpretation
What improved
Vs prior year
- ↑
Equity
15.0m → 18.5m NOK [R2025]
What deteriorated
Vs prior year
Buyer profile
What they may buy next
Sales-oriented read of industry, stage, filings, and registry signals — what this company is likely to purchase or hire over the next year. Interpretive, not a stated budget.
Health metrics
Ratios from the accounts
Source citations
Every material claim traces here
- [R2021] Årsregnskap 2021 · journal — · approved — · registry —
- [R2022] Årsregnskap 2022 · journal 2023 651435 · approved 27.04.2023 · registry 07.08.2023
- [R2023] Årsregnskap 2023 · journal 2024 593445 · approved 16.04.2024 · registry 08.07.2024
- [R2024] Årsregnskap 2024 · journal 2025 688190 · approved 12.03.2025 · registry 23.07.2025
- [R2025] Årsregnskap 2025 · journal 2026 571012 · approved 07.04.2026 · registry 13.07.2026
Original annual reports
Source documents
Årsregnskap 2025
Approved 07.04.2026
Fee deadline 31.07.2026
Registry 13.07.2026
On time vs fee deadline
Årsregnskap 2024
Approved 12.03.2025
Fee deadline 31.07.2025
Registry 23.07.2025
On time vs fee deadline
Årsregnskap 2023
Approved 16.04.2024
Fee deadline 31.07.2024
Registry 08.07.2024
On time vs fee deadline
Årsregnskap 2022
Approved 27.04.2023
Fee deadline 31.07.2023
Registry 07.08.2023
Signals
Hard · medium · soft
Derived from published accounts, Brreg roles, and kunngjøringer. Soft signals are interpretive — not facts or buying proof.
Registered address
Where the company sat over time
From Brreg «Endring av forretningsadresse» filings. Hubs and c/o addresses are tagged so you can see the path from incubator to own office.
Board & management
Who joined and left
Diffed from Styre / Daglig leder kunngjøringer (full public history).
Løsøreregisteret
Heftelser & rettsstiftelser
Active pant / utlegg and other registrations from Brreg’s public rettsstiftelser oppslag (not a full credit report).
Kunngjøringer
Full registry history
Ownership
Owners, officers & filing notes
Prefer Skatteetaten’s Aksjonærregisteret when available. Otherwise FirmaIQ shows Brreg officers (name + birth date) and any shareholder names disclosed in the annual-report «Aksjeeiere» note.